Table 2.
Clinical characteristics and fasting blood concentrations of several metabolic variables after 10 days of exenatide and placebo treatment in 36 patients completing crossover study 1
| Placebo | Exenatide | Change* | P value | |
|---|---|---|---|---|
| Body weight (kg) | 101.4 ± 22 | 100.7 ± 21.5 | −0.95 (−2 to 0.6) | 0.01 |
| Systolic blood pressure (mmHg) | 131 ± 11 | 126 ± 13 | −5.5 (−14 to 9) | 0.03 |
| Diastolic blood pressure (mmHg) | 76 ± 9 | 76 ± 10 | 1 (−5 to 6.5) | 0.9 |
| Heart rate (bpm) | 69 ± 12 | 71 ± 11 | 1.5 (−5.5 to 5.5) | 0.2 |
| Glucose (mg/dL) | 122 ± 25 | 113 ± 23 | −7.5 (−17.5 to 3.5) | 0.01 |
| Insulin (mU/L) | 12.3 (8.6–24) | 13.2 (8.8–25.6) | 0.8 (−1.5 to 4.4) | 0.2 |
| Triglycerides (mg/dL) | 186 ± 104 | 172 ± 77 | −16 (−51 to 34) | 0.4 |
| Total cholesterol (mg/dL) | 163 ± 36 | 150 ± 33 | −10 (−27 to 3) | 0.002 |
| LDL cholesterol (mg/dL) | 80 ± 10 | 81 ± 28 | 7 (−11 to 21) | 0.8 |
| HDL cholesterol (mg/dL) | 38 ± 8 | 36 ± 7 | −1 (−6 to 2) | 0.048 |
Data are means ± SD or medians (25th–75th percentile). P values indicate comparison between the two treatment arms by repeated-measures ANCOVA adjusted for treatment sequence and diabetes duration group.
*Exenatide minus placebo.